Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
GRANULES.NS
Strong BuyPremium GrowerGranules India Limited · Healthcare · India · $2.3B · Avg Vol: $7M/d
87
StockRankGet insider-trade alerts
Q
69
V
31
M
85
P/E (TTM)
32.8x
ROE
11.7%
D/E
0.3x
Dividend %
0.2%
COMPANY DESCRIPTION
Granules India Limited manufactures and sells active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates (PFIs), finished dosages (FDs), and peptides CDMO in India and internationally.
FINANCIAL SUMMARY (INR)
| Year | 2023 | 2024 | 2025 | 2026 | CAGR | TTM | 2027E | 2028E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 45.0B | 44.9B | 44.6B | 53.4B | 5.9% | 56.3B | 62.7B | 72.1B | 16.2% |
| EPS (INR) | 21.05 | 16.73 | 20.69 | 24.47 | 5.1% | 26.95 | 31.13 | 39.23 | 26.6% |
| Shares | 242.0M | 242.4M | 242.5M | 247.8M | +2.4% | 247.8M | — | — | — |
| Debt | 11.4B | 13.2B | 14.5B | 15.1B | 10.0% | 15.1B | — | — | — |
| Equity | 28.3B | 32.3B | 37.2B | 50.8B | 21.5% | — | — | — | — |
| Op CF | 7.4B | 4.4B | 8.7B | 7.9B | 2.4% | 7.9B | — | — | — |
| Inv CF | -1.9B | -3.6B | -6.9B | -7.7B | — | — | — | — | — |
| Fin CF | -4.4B | 76.6M | -925.1M | 3.8B | — | — | — | — | — |
Loading 1Y...
PRICE (1Y)+6.1%
SMA 50SMA 200
Close
$9.30
RSI (14)
63.3
52W High
$9.55
From 52W High
1.0%
SCORE BREAKDOWN
Quality
69
ROIC
17.6%88.1
ROE
11.7%75.2
GP/Assets
45.2%82.7
Op. Margin
17.6%79.5
FCF/Assets
3.0%60.4
Piotroski
668.8
Int. Cover
8.9x60.2
D/E Ratio
0.30x41.0
Current Ratio
1.80x34.6
Value
31
P/E (TTM)
32.8x36.8
EV/EBITDA
18.0x39.2
P/FCF
94.7x16.5
P/B
4.3x33.8
P/S
3.9x49.2
Div Yield
0.2%4.4
Momentum
85
52W High %
97%97.8
RS 6M
55%92.1
SMA 50/200
1.23x89.7
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
+47%53.0
Q Growth
60%76.8
FUNDAMENTALS
Market Cap
$2.3B
P/E (Forward)
22.3x
Gross Margin
62.0%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of GRANULES.NS are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| GRANULES.NS | Granules India Limited(you) | $2.3B | 87 | Strong Buy |
| CAPLIPOINT.NS | Caplin Point Laboratories Limited | $2.2B | 86 | Strong Buy |
| ALIVUS.NS | Alivus Life Sciences Limited | $1.8B | 91 | Strong Buy |
| APLLTD.NS | Alembic Pharmaceuticals Limited | $1.7B | 84 | Strong Buy |
| VIYASH.NS | Viyash Scientific Limited | $1.2B | 88 | Strong Buy |
| EMCURE.NS | Emcure Pharmaceuticals Limited | $3.9B | 81 | Strong Buy |
| GLAND.NS | Gland Pharma Limited | $5.1B | 88 | Strong Buy |
| STAR.NS | Strides Pharma Science Limited | $1.2B | 93 | Strong Buy |
| IPCALAB.NS | Ipca Laboratories Limited | $5.3B | 91 | Strong Buy |
| BLISSGVS.NS | Bliss GVS Pharma Limited | $810M | 87 | Strong Buy |
Peer medians: ROE 11.9% · P/E 42.8x · Gross margin 59.4%